Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice

Journal of Immunology

Volumn 170, Issue 12, 2003, Pages 6158-6164

  Saeland, Eirikur ^a   Vidarsson, Gestur ^a,b   Leusen, Jeanette H W ^a   Van Garderen, Evert ^c   Nahm, Moon H ^d   Vile Weekhout, Henriette ^e   Walraven, Vanessa ^a   Stemerding, Annette M ^a   Verbeek, J Sjef ^f   Rijkers, Ger T ^a   Kuis, Wietse ^a   Sanders, Elisabeth A M ^a   Van de Winkel, Jan G J ^a,e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d University of Alabama at Birmingham   (United States)

^e GENMAB   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; PNEUMOCOCCUS VACCINE; RECOMBINANT ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL MEMBRANE; BACTERIAL STRAIN; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT FACTOR; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HISTOPATHOLOGY; HUMAN; HYPEREMIA; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LEUKOCYTE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SEPTIC SHOCK; SPLEEN; STREPTOCOCCUS INFECTION; THROMBOGENESIS; THROMBOSIS; WILD TYPE;

EID: 0038619043     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.12.6158     Document Type: Article

References (56)

1. Fedson, D. S., J. A. Scott, and G. Scott. 1999. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17(Suppl. 1):S11.
2. Klein, J. O. 1981. The epidemiology of pneumococcal disease in infants and children. Rev. Infect. Dis. 3:246.
3. Lortan, J. E., A. S. Kaniuk, and M. A. Monteil. 1993. Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin. Exp. Immunol. 91:54.
4. Musher, D. M., A. J. Chapman, A. Goree, S. Jonsson, D. Briles, and R. E. Baughn. 1986. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154:245.
5. Shapiro, E. D., A. T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Margolis, R. K. Adair, and J. D. Clemens. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453.
6. Karma, P., J. Pukander, M. Sipila, M. Timonen, S. Pontynen, E. Herva, P. Gronroos, and H. Makela. 1985. Prevention of otitis media in children by pneumococcal vaccination. Am. J. Otolaryngol. 6:173.
7. Black, S. B., H. R. Shinefield, J. Hansen, L. Elvin, D. Laufer, and F. Malinoski. 2001. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccines. Pediatr. Infect. Dis. J. 20:1105.
8. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, R. Kohberger, et al. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403.
9. Barrett, D. J., and E. M. Ayoub. 1986. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63:127.
10. Lottenbach, K. R., C. M. Mink, S. J. Barenkamp, E. L. Anderson, S. M. Homan, and D. C. Powers. 1999. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect. Immun. 67:4935.
11. Soininen, A., I. Seppala, T. Nieminen, J. Eskola, and H. Kayhty. 1999. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17:1889.
12. Vidarsson, G., and J. G. J. van de Winkel. 1998. Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr. Opin. Infect. Dis. 11:271.
13. Fridman, W. H., C. Bonnerot, M. Daeron, S. Amigorena, J. L. Teillaud, and C. Sautes. 1992. Structural bases of Fcγ receptor functions, Immunol. Rev. 125:49.
14. Taylor, P., M. Botto; and M. Walport. 1998. The complement system. Curr. Biol. 8:R259.
15. Brown, E. J. 1991. Complement receptors and phagocytosis. Curr. Opin. Immunol. 3:76.
16. Jansen, W. T., M. A. Breukels, H. Snippe, L. A. M. Sanders, A. F. Verheul, and G. T. Rijkers. 1999. Fcγ receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera. J. Infect. Dis. 180:888.
17. Rodriguez, M. E., W. L. van der Pol, L. A. M. Sanders, and J. G. J. van de Winkel. 1999. Crucial role of FcγRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J. Infect. Dis. 179:423.
18. Winkelstein. J. A. 1981. The role of complement in the host's defense against Streptococcus pneumoniae. Rev. Infect. Dis. 3:289.
19. Neeleman, C., S. P. Geelen, P. C. Aerts, M. R. Daha, T. E. Mollnes, J. J. Roord, G. Posthuma, H. van Dijk, and A. Fleer. 1999. Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect. Immun. 67:4517.
20. Hostetter, M. K. 1986. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J. Infect. Dis. 153:682.
21. Gross, G. N., S. R. Rehm, and A. K. Pierce. 1978. The effect of complement depletion on lung clearance of bacteria. J. Clin. Invest. 62:373.
22. Brown, E. J., K. A. Joiner, R. M. Cole, and M. Berger. 1983. Localization of complement component 3 on Streprococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect. Immun. 39:403.
23. Frank, M. M. 1992. The mechanism by which microorganisms avoid complement attack. Curr. Opin. Immunol. 4:14.
24. Szalai, A. J., D. E. Briles, and J. E. Volanakis. 1996. Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect. Immun. 64:4850.
25. Mold, C., B. Rodic-Polic, and T. W. Du Clos. 2002. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fcγ receptors. J. Immunol. 168:6375.
26. Brown, E. J., S. W. Hosea, C. H. Hammer, C. G. Burch, and M. M. Frank. 1982. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J. Clin. Invest. 69:85.
27. Briles, D. E., C. Forman, J. C. Horowitz, J. E. Volanakis, W. H. Benjamin, Jr., L. S. McDaniel, J. Eldridge, and J. Brooks. 1989. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect. Immun. 57:1457.
28. Aase, A., and T. E. Michaelsen. 1994. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand. J. Immunol. 39:581.
29. Sun, Y., M. K. Park, J. Kim, B. Diamond, A. Solomon, and M. H. Nahm. 1999. Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B. Infect. Immun. 67:1172.
30. Vidarsson, G., J. G. J. van de Winkel, and M. A. van Dijk. 2001. Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes. J. Immunol. Methods 249:245.
31. Boel, E., S. Verlaan, M. J. Poppelier, N. A. Westerdaal, J. A. van Strijp, and T. Logtenberg. 2000. Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J. Immunol. Methods 239:153.
32. Sigurdardottir, S. T., G. Vidarsson, T. Gudnason, S. Kjartansson, K. G. Kristinsson, S. Jonsson, H. Valdimarsson, G. Schiffman, R. Schneerson, and I. Jonsdottir. 1997. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr. Infect. Dis. J. 16:667.
33. Taylor, P. R., J. T. Nash, E. Theodoridis, A. E. Bygrave, M. J. Walport, and M. Botto. 1998. A targeted disruption of the murine complement factor B gene resulting in loss of expression of three genes in close proximity, factor B, C2, and D17H6S45. J. Biol. Chem. 273:1699.
34. Botto, M., C. Dell'Agnola, A. E. Bygrave, E. M. Thompson, H. T. Cook, F. Petry. M. Loos, P. P. Pandolfi, and M. J. Walport. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:56.
35. Park, S. Y., S. Ueda, H. Ohno, Y. Hamano, M. Tanaka, T. Shiratori, T. Yamazaki, H. Arase, N. Arase, A. Karasawa, et al. 1998. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102:1229.
36. Ioan-Facsinay, A., S. J. de Kimpe, S. M. Hellwig, P. L. van Lent, F. M. Hofhuis, H. H. van Ojik, C. Sedlik, S. A. da Silveira, J. Gerber, Y. F. de Jong, et al. 2002. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16:391.
37. Van Spriel, A. B., I. van den Herik-Oudijk, and J. G. J. van de Winkel. 2000. A single injection of polyethylene-glycol granulocyte colony-stimulating factor strongly prolongs survival of mice with systemic candidiasis. Cytokine 12:666.
38. Jones, B., J. P. Tite, and C. A. Janeway, Jr. 1986. Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones. J. Immunol. 136:348.
39. McIlman, I. S., and J. C. Unkeless. 1980. Purification of a functional mouse Fc receptor through the use of a monoclonal antibody. J. Exp. Med. 152:1048.
40. Huizinga, T. W., M. Kerst, J. H. Nuyens, A. Vlug, A. E. dem Borne, D. Roos, and P. A. Tetteroo. 1989. Binding characteristics of dimeric IgG subclass complexes to human neutrophils. J. Immunol. 142:2359.
41. Rodriguez, M. E., W. L. van der Pol, and J. G. J. van De Winkel. 2001. Flow cytometry-based phagocytosis assay for sensitive detection of opsonic activity of pneumococcal capsular polysaccharide antibodies in human sera. J. Immunol. Methods 252:33.
42. Xu, Y., M. Ma, G. C. Ippolito, H. W. Schroeder, Jr., M. C. Carroll, and J. E. Volanakis. 2001. Complement activation in factor D-deficient mice. Proc. Natl. Acad. Sci. USA 98:14577.
43. Saeland, E., G. Vidarsson, and I. Jonsdottir. 2000. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb. Pathog. 29:81.
44. Saeland, E., H. Jakobsen, G. Ingolfsdottir, S. T. Sigurdardottir, and I. Jonsdottir. 2000. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J. Infect. Dis. 183:253.
45. Beukelman, C. J., P. C. Aerts, H. van Dijk, and J. M. Willers. 1987. A one-step isolation procedure for phospholipase A2-free cobra venom factor by fast protein liquid chromatography. J. Immunol. Methods 97:119.
46. Van den Berg, C. W., P. C. Aerts, and H. van Dijk. 1991. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje. J. Immunol. Methods 136:287.
47. Klerx, J. P., C. J. Beukelman, H. van Dijk, and J. M. Willers. 1983. Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J. Immunol. Methods 63:215.
48. Ravetch, J. V. 1994. Fc receptors: rubor redux. Cell 78:553.
49. Lauw, F. N., J. Branger, S. Florquin, P. Speelman, S. J. van Deventer, S. Akira, and T. van der Poll. 2002. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J. Immunol. 168:372.
50. Rijneveld, A. W., S. Florquin, J. Branger, P. Speelman, S. J. van Deventer, and T. van der Poll. 2001. TNF-α compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J. Immunol. 167:5240.
51. Takashima, K., K. Tateda, T. Matsumoto, Y. Iizawa, M. Nakao, and K. Yamaguchi. 1997. Role of tumor necrosis factor α in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 65:257.
52. Weinberg, G. A., D. M. Granoff, M. H. Nahm, and P. G. Shackelford. 1986. Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of Haemophilus influenzae. J. Immunol. 136:4232.
53. Dallaire, F., N. Ouellet, M. Simard, Y. Bergeron, and M. G. Bergeron. 2001. Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment. J. Infect. Dis. 183:70.
54. Sundsmo, J. S., and D. S. Fair. 1983. Relationships among the complement, kinin, coagulation, and fibrinolytic systems. Springer Semin. Immunopathol. 6:231.
55. Sims, P. J., and T. Wiedmer. 1991. The response of human platelets to activated components of the complement system. Immunol. Today 12:338.
56. Ozge-Anwar, A. H., J. J. Freedman. A. F. Senyi, A. L. Cerskus, and M. A. Blajchman. 1984. Enhanced prothrombin-converting activity and factor Xa binding of platelets activated by the alternative complement pathway. Br. J. Haematol. 57:221.